Literature DB >> 26455823

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach.

Evren Alici1,2,3, Michael Chrobok1,3, Johan Lund1,2, Tahamtan Ahmadi4, Imran Khan4, Adil D Duru1,3, Hareth Nahi5,6,7.   

Abstract

Entities:  

Keywords:  CD38; daratumumab; relapsed and refractory multiple myeloma; response

Mesh：

Substances：

Year:  2015        PMID： 26455823     DOI： 10.1111/bjh.13776

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

Review 1.  Integration of Novel Agents into the Care of Patients with Multiple Myeloma.

Authors:  Robert Z Orlowski; Sagar Lonial
Journal:  Clin Cancer Res       Date:  2016-11-14       Impact factor: 12.531

Review 2.  Immunotherapies targeting CD38 in Multiple Myeloma.

Authors:  Djordje Atanackovic; Mary Steinbach; Sabarinath Venniyil Radhakrishnan; Tim Luetkens
Journal:  Oncoimmunology       Date:  2016-08-05       Impact factor: 8.110

Review 3.  Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

Authors:  Philippe Moreau; Niels W C J van de Donk; Jesus San Miguel; Henk Lokhorst; Hareth Nahi; Dina Ben-Yehuda; Michele Cavo; Gordon Cook; Michel Delforge; Hermann Einsele; Sonja Zweegman; Heinz Ludwig; Christoph Driessen; Antonio Palumbo; Thierry Facon; Torben Plesner; Meletios Dimopoulos; Pia Sondergeld; Pieter Sonneveld; María-Victoria Mateos
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

4.  Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumumab.

Authors:  Jakub Krejcik; Kris A Frerichs; Inger S Nijhof; Berris van Kessel; Jeroen F van Velzen; Andries C Bloem; Marloes E C Broekmans; Sonja Zweegman; Johan van Meerloo; René J P Musters; Pino J Poddighe; Richard W J Groen; Christopher Chiu; Torben Plesner; Henk M Lokhorst; A Kate Sasser; Tuna Mutis; Niels W C J van de Donk
Journal:  Clin Cancer Res       Date:  2017-10-12       Impact factor: 12.531

5.  The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma.

Authors:  Nina Shah; Jack Aiello; David E Avigan; Jesus G Berdeja; Ivan M Borrello; Ajai Chari; Adam D Cohen; Karthik Ganapathi; Lissa Gray; Damian Green; Amrita Krishnan; Yi Lin; Elisabet Manasanch; Nikhil C Munshi; Ajay K Nooka; Aaron P Rapoport; Eric L Smith; Ravi Vij; Madhav Dhodapkar
Journal:  J Immunother Cancer       Date:  2020-07       Impact factor: 13.751

6.  Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second-line lenalidomide + dexamethasone induction in multiple myeloma.

Authors:  Johan Lund; Astrid Gruber; Birgitta Lauri; Adil Doganay Duru; Cecilie Blimark; Agneta Swedin; Markus Hansson; Karin Forsberg; Lucia Ahlberg; Conny Carlsson; Anders Waage; Peter Gimsing; Annette Juul Vangsted; Ulf Frølund; Erik Holmberg; Gösta Gahrton; Evren Alici; Mats Hardling; Ulf-Henrik Mellqvist; Hareth Nahi
Journal:  Cancer Med       Date:  2018-04-19       Impact factor: 4.452

7.  Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma.

Authors:  Hareth Nahi; Michael Chrobok; Charlotte Gran; Johan Lund; Astrid Gruber; Gösta Gahrton; Per Ljungman; Arnika Kathleen Wagner; Evren Alici
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.240

Review 8.  CD38 Expression by Myeloma Cells and Its Role in the Context of Bone Marrow Microenvironment: Modulation by Therapeutic Agents.

Authors:  Federica Costa; Benedetta Dalla Palma; Nicola Giuliani
Journal:  Cells       Date:  2019-12-13       Impact factor: 6.600

9.  Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma.

Authors:  Maximilian Johannes Steinhardt; Xiang Zhou; Franziska Krummenast; Katharina Meckel; Katharina Nickel; David Böckle; Janin Messerschmidt; Sebastian Knorz; Alexander Dierks; Anke Heidemeier; Constantin Lapa; Hermann Einsele; Leo Rasche; Klaus Martin Kortüm
Journal:  Int J Immunopathol Pharmacol       Date:  2020 Jan-Dec       Impact factor: 3.219

Review 10.  Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.

Authors:  Laurens E Franssen; Claudia A M Stege; Sonja Zweegman; Niels W C J van de Donk; Inger S Nijhof
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.